OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$11.72
0.05 (0.43%)
▲
5d:
+0.95%
30d:
-62.19%
90d:
-52.36%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OCS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: OCS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $11.72, which is considered slightly low relative to its 30-day fair value range of $9.79 to $26.62.
Technical Outlook: Technically, OCS is in a downtrend. Immediate support is located at $10.65, while resistance sits at $12.17.
Market Sentiment: OCS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.41 (+219.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OCS is in a downtrend. Immediate support is located at $10.65, while resistance sits at $12.17.
Market Sentiment: OCS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $37.41 (+219.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$9.79 -
$26.62
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 219.2% below Wall St target ($37.41)
Trading Range Analysis
30-Day Trading Range
$9.79 -
$26.62
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.14
(9.7%)
Support & Resistance Levels
Support Level
$10.65
Resistance Level
$12.17
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.16
Wall Street Target
$37.41
(+219.2%)
Revenue Growth (YoY)
-26.7%
Share & Embed Analysis
Last updated: June 23, 2026 11:44 PM ET
Data refreshes hourly during market hours. Next update: 12:44 AM
Data refreshes hourly during market hours. Next update: 12:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
